Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Van Cutsem

Showing results (81-90 of 499) with videos related to

Pageof 50
Sort By:
Journal of the Belgian Society of Radiology|July 25, 2020
Characterization of Liver Metastases During Catheter-Directed Liver Interventions: A Comparison between Dual Phase Cone-Beam Computed Tomography and Conventional Contrast-Enhanced Computed TomographyGeert Maleux, Maria-Louisa Izamis, Cedric Werbrouck, et al.
Translational Oncology|December 18, 2016
Acriflavine Inhibits Acquired Drug Resistance by Blocking the Epithelial-to-Mesenchymal Transition and the Unfolded Protein ResponseJeroen Dekervel, Ashenafi Bulle, Petra Windmolders, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2012
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumabMarc Peeters, Jean-Yves Douillard, Eric Van Cutsem, et al.
Oncotargets and Therapy|August 9, 2020
Anti-Cancer Activity of Acriflavine as Metabolic Inhibitor of OXPHOS in Pancreas Cancer XenograftsAshenafi Bulle, Jeroen Dekervel, Lise Deschuttere, et al.
Journal of Translational Medicine|May 11, 2023
Human pancreatic cancer patients with Epithelial-to-Mesenchymal Transition and an aggressive phenotype show a disturbed balance in Protein Phosphatase Type 2A expression and functionalityJos van Pelt, Bob Meeusen, Rita Derua, et al.
The Oncologist|February 17, 2024
Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic ReviewKohei Shitara, Alfred Falcone, Marwan G Fakih, et al.
The Lancet. Oncology|May 1, 2007
Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective studySabine Tejpar, Hubert Piessevaux, Kathleen Claes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapySandra Van Schaeybroeck, Anthi Karaiskou-McCaul, Donal Kelly, et al.
Annals of Surgical Oncology|March 28, 2012
Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcomeAlbert M Wolthuis, Freddy Penninckx, Karin Haustermans, et al.
Cancer Letters|November 1, 2012
Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growthHannah van Malenstein, Jeroen Dekervel, Chris Verslype, et al.
Pageof 50

Showing results (81-90 of 499) with videos related to

Sort By:
Pageof 50
Journal of the Belgian Society of Radiology|July 25, 2020
Characterization of Liver Metastases During Catheter-Directed Liver Interventions: A Comparison between Dual Phase Cone-Beam Computed Tomography and Conventional Contrast-Enhanced Computed TomographyGeert Maleux, Maria-Louisa Izamis, Cedric Werbrouck, et al.
Translational Oncology|December 18, 2016
Acriflavine Inhibits Acquired Drug Resistance by Blocking the Epithelial-to-Mesenchymal Transition and the Unfolded Protein ResponseJeroen Dekervel, Ashenafi Bulle, Petra Windmolders, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2012
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumabMarc Peeters, Jean-Yves Douillard, Eric Van Cutsem, et al.
Oncotargets and Therapy|August 9, 2020
Anti-Cancer Activity of Acriflavine as Metabolic Inhibitor of OXPHOS in Pancreas Cancer XenograftsAshenafi Bulle, Jeroen Dekervel, Lise Deschuttere, et al.
Journal of Translational Medicine|May 11, 2023
Human pancreatic cancer patients with Epithelial-to-Mesenchymal Transition and an aggressive phenotype show a disturbed balance in Protein Phosphatase Type 2A expression and functionalityJos van Pelt, Bob Meeusen, Rita Derua, et al.
The Oncologist|February 17, 2024
Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic ReviewKohei Shitara, Alfred Falcone, Marwan G Fakih, et al.
The Lancet. Oncology|May 1, 2007
Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective studySabine Tejpar, Hubert Piessevaux, Kathleen Claes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapySandra Van Schaeybroeck, Anthi Karaiskou-McCaul, Donal Kelly, et al.
Annals of Surgical Oncology|March 28, 2012
Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcomeAlbert M Wolthuis, Freddy Penninckx, Karin Haustermans, et al.
Cancer Letters|November 1, 2012
Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growthHannah van Malenstein, Jeroen Dekervel, Chris Verslype, et al.
Pageof 50